Intravesicale onabotulinumtoxine-A-injecties bij therapieresistente kinderen met een niet-neurogene overactieve blaas

Annemarth P. Lambregts; Anka J. Nieuwhof-Leppink; Aart J. Klijn; Rogier P.J. Schroeder

doi:10.1007/s13629-022-00360-3

Intravesicale onabotulinumtoxine-A-injecties bij therapieresistente kinderen met een niet-neurogene overactieve blaas

Translated title of the contribution: Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder

Annemarth P. Lambregts, Anka J. Nieuwhof-Leppink^*, Aart J. Klijn, Rogier P.J. Schroeder

^*Corresponding author for this work

Incontinence team

Research output: Contribution to journal › Article › Academic › peer-review

16 Downloads (Pure)

Abstract

Overactive bladder (OAB) with urinary incontinence poses a potentially significant impact on daily activities and quality of life. Due to its successful outcomes in the treatment of neurogenic bladder, intravesical botulinum‑A toxin (BTX-A) became a possible solution for children refractory to treatment. 50 children (41 boys) with a median age of 9.9 years were included. In the short term, there was a significant increase in FBV after initial BTX‑A treatment. In the short (< 6 months) and long term (6–12 months) 72 and 46% showed improvement of continence, respectively. Male gender and small baseline FBV predict a positive outcome on continence in the long term. In refractory OAB children, BTX‑A injections are safe and effective in enlarging bladder volume and reducing OAB symptoms, particularly in the first six months after injection.

Translated title of the contribution	Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder
Original language	Dutch
Pages (from-to)	96-103
Number of pages	8
Journal	Tijdschrift voor Urologie
Volume	12
Issue number	5
DOIs	https://doi.org/10.1007/s13629-022-00360-3
Publication status	Published - Aug 2022

Keywords

botulinum toxins type A
overactive bladder
pediatrics
urinary incontinence

Access to Document

10.1007/s13629-022-00360-3Licence: CC BY

s13629-022-00360-3Final published version, 317 KBLicence: CC BY

Cite this

@article{ab7ab06eae7540208f0d3e443015a5c6,

title = "Intravesicale onabotulinumtoxine-A-injecties bij therapieresistente kinderen met een niet-neurogene overactieve blaas",

abstract = "Overactive bladder (OAB) with urinary incontinence poses a potentially significant impact on daily activities and quality of life. Due to its successful outcomes in the treatment of neurogenic bladder, intravesical botulinum‑A toxin (BTX-A) became a possible solution for children refractory to treatment. 50 children (41 boys) with a median age of 9.9 years were included. In the short term, there was a significant increase in FBV after initial BTX‑A treatment. In the short (< 6 months) and long term (6–12 months) 72 and 46% showed improvement of continence, respectively. Male gender and small baseline FBV predict a positive outcome on continence in the long term. In refractory OAB children, BTX‑A injections are safe and effective in enlarging bladder volume and reducing OAB symptoms, particularly in the first six months after injection.",

keywords = "botulinum toxins type A, overactive bladder, pediatrics, urinary incontinence",

author = "Lambregts, {Annemarth P.} and Nieuwhof-Leppink, {Anka J.} and Klijn, {Aart J.} and Schroeder, {Rogier P.J.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = aug,

doi = "10.1007/s13629-022-00360-3",

language = "Dutch",

volume = "12",

pages = "96--103",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "5",

}

TY - JOUR

T1 - Intravesicale onabotulinumtoxine-A-injecties bij therapieresistente kinderen met een niet-neurogene overactieve blaas

AU - Lambregts, Annemarth P.

AU - Nieuwhof-Leppink, Anka J.

AU - Klijn, Aart J.

AU - Schroeder, Rogier P.J.

PY - 2022/8

Y1 - 2022/8

N2 - Overactive bladder (OAB) with urinary incontinence poses a potentially significant impact on daily activities and quality of life. Due to its successful outcomes in the treatment of neurogenic bladder, intravesical botulinum‑A toxin (BTX-A) became a possible solution for children refractory to treatment. 50 children (41 boys) with a median age of 9.9 years were included. In the short term, there was a significant increase in FBV after initial BTX‑A treatment. In the short (< 6 months) and long term (6–12 months) 72 and 46% showed improvement of continence, respectively. Male gender and small baseline FBV predict a positive outcome on continence in the long term. In refractory OAB children, BTX‑A injections are safe and effective in enlarging bladder volume and reducing OAB symptoms, particularly in the first six months after injection.

AB - Overactive bladder (OAB) with urinary incontinence poses a potentially significant impact on daily activities and quality of life. Due to its successful outcomes in the treatment of neurogenic bladder, intravesical botulinum‑A toxin (BTX-A) became a possible solution for children refractory to treatment. 50 children (41 boys) with a median age of 9.9 years were included. In the short term, there was a significant increase in FBV after initial BTX‑A treatment. In the short (< 6 months) and long term (6–12 months) 72 and 46% showed improvement of continence, respectively. Male gender and small baseline FBV predict a positive outcome on continence in the long term. In refractory OAB children, BTX‑A injections are safe and effective in enlarging bladder volume and reducing OAB symptoms, particularly in the first six months after injection.

KW - botulinum toxins type A

KW - overactive bladder

KW - pediatrics

KW - urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=85133169282&partnerID=8YFLogxK

U2 - 10.1007/s13629-022-00360-3

DO - 10.1007/s13629-022-00360-3

M3 - Article

AN - SCOPUS:85133169282

SN - 2211-3037

VL - 12

SP - 96

EP - 103

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 5

ER -

Intravesicale onabotulinumtoxine-A-injecties bij therapieresistente kinderen met een niet-neurogene overactieve blaas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this